(+)-4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylic Acid | 263769-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (+)-4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylic Acid
• 英文别名: (3R,4S)-4-(4-Chloro-phenyl)-1-methyl-piperidine-3-carboxylic acid；(3R,4S)-4-(4-chlorophenyl)-1-methylpiperidine-3-carboxylic acid
• CAS: 263769-44-4
• 化学式: C₁₃H₁₆ClNO₂
• 分子量: 253.729
• InChiKey: VZRKPBMFNYPIGP-NEPJUHHUSA-N

物化性质

• 沸点：
  393.3±42.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+)-4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylic Acid 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 生成
  参考文献：
  名称：

  SAR Studies of Piperidine-Based Analogues of Cocaine. Part 3: Oxadiazoles

  摘要：

  The synthesis of novel 4 beta -aryl-1-methyl-3 alpha-(3-substituted-1,2,4-oxadiazol-5-yl)piperidines, bioisosteres of ester (+)-1, is described. The synthesized oxadiazoles were evaluated for their affinity to the DAT and their ability to inhibit monoamine reuptake at the DAT. NET, and 5HTT. The results show that affinity to the DAT and ability to inhibit the reuptake at the DAT, NET, and 5HTT is a function of the size of the substituent in the oxadiazole ring. (+)-(3R,4S)-4 beta-(4-Chlorophenyl)-1-methyl-3 alpha-(3-methyl-1,2,4-oxadiazol-5-yl)piperidine [(+)-2a], which is structurally and pharmacologically most similar to the ester (+)-1 in this series, showed at least a 2-fold longer duration of action when compared to ester (+)-1. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00379-1
• 作为产物：
  描述：

  槟榔碱 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 (+)-4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylic Acid
  参考文献：
  名称：

  二价配体方法在新型二聚血清素再摄取抑制剂设计中的应用

  摘要：

  DOI：

  10.1021/ja000199f

文献信息

• Synthesis and biological evaluation of 1-azabicyclo-[3.2.1]octanes: new dopamine transporter inhibitors
  作者：Amir P Tamiz、Miles P Smith、Istvan Enyedy、Judith Flippen-Anderson、Mei Zhang、Kenneth M Johnson、Alan P Kozikowski

  DOI：10.1016/s0960-894x(00)00308-5

  日期：2000.8

  The synthesis and biological activity of a series of 6-substituted 1-azabicyclo[3.2.1]octanes are described. 1-Azabicyclo[3.2.1]octanes represent a new class of compounds that exhibit monoamine transporter inhibitory activity highly dependent on the overall topology and the absolute stereochemistry of the molecule.

  描述了一系列6-取代的1-氮杂双环[3.2.1]辛烷的合成和生物活性。1-氮杂双环[3.2.1]辛烷代表一类新的化合物，这些化合物表现出高度依赖于分子的整体拓扑结构和绝对立体化学的单胺转运蛋白抑制活性。
• Monomeric and dimeric heterocycles, and therapeutic uses thereof
  申请人：Georgetown University

  公开号：US06440996B1

  公开（公告）日：2002-08-27

  The invention provides compounds of formula (I): X—L—X1  (I) wherein X and X1 are substituted piperidine, cyclohexane, or tetrahydropyran rings, and L is a linking group between X and X1; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.

  该发明提供了以下式（I）的化合物：X—L—X1（I），其中X和X1为取代的哌啶、环己烷或四氢吡喃环，L为连接X和X1之间的连接基团；以及包括式I化合物的药物组合物；用于制备式I化合物的中间体和方法；以及治疗药物成瘾、帕金森病、抑郁症或需要使用可卡因的疾病的治疗方法，包括向需要此类治疗的哺乳动物施用式I化合物或其药用盐。
• [EN] ANALOGS OF COCAINE<br/>[FR] ANALOGUES DE COCAINE
  申请人：GEORGETOWN UNIVERSITY

  公开号：WO1998045263A1

  公开（公告）日：1998-10-15

  (EN) The invention provides a compound of formula (I), wherein R1, R2, R3, and Y have any of the meanings defined in the specification; as well as a pharmaceutical composition comprising a compound of formula (I); intermediates and methods useful for preparing a compound of formula (I); and therapeutic methods for treating drug addiction, Parkinson's disease or depression comprising administering a compound of formula (I), to a mammal in need of such treatment.(FR) L'invention concerne un composé de formule (I) dans laquelle R1, R2, R3 et Y ont n'importe laquelle des définitions figurant dans la description, ainsi qu'une composition pharmaceutique comprenant un composé de formule (I), des intermédiaires et des procédés utiles à la préparation d'un composé de formule (I) ainsi que des méthodes thérapeutiques de traitement de la toxicomanie, de la maladie de Parkinson ou de la dépression consistant à administrer un composé de formule (I) à un mammifère nécessitant un tel traitement.

  该发明提供了一种化合物，其化学式为(I)，其中R1、R2、R3和Y具有规范中定义的任何含义；以及包含化合物(I)的药物组合物；用于制备化合物(I)的中间体和方法；以及治疗药物成瘾、帕金森病或抑郁症的治疗方法，包括向需要此类治疗的哺乳动物给予化合物(I)。
• [EN] MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF<br/>[FR] HETEROCYCLES MONOMERES ET DIMERES ET LEURS UTILISATIONS THERAPEUTIQUES
  申请人：UNIV GEORGETOWN

  公开号：WO2000020390A1

  公开（公告）日：2000-04-13

  The invention provides compounds of the formula (I) X-L-X1 wherein X, L, and X1 have any of the meanings defined in the specification; as well as a pharmaceutical composition comprising a compound of formula (I); intermediates and methods useful for preparing a compound of formula (I); and therapeutic methods for treating drug addiction, Parkinson's disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.

  本发明提供公式（I）X-L-X1的化合物，其中X，L和X1具有规范中定义的任何含义；以及包含公式（I）化合物的药物组合物；制备公式（I）化合物有用的中间体和方法；以及用于治疗药物成瘾、帕金森病、抑郁症或需要使用可卡因的疾病的治疗方法，包括将公式（I）化合物或其药学上可接受的盐用于需要此类治疗的哺乳动物的治疗中。
• Medical fluid, a method of treatment and use of the fluid
  申请人：XVIVO PERFUSION AB

  公开号：US10271540B2

  公开（公告）日：2019-04-30

  A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analog thereof; noradrenaline; and/or adrenaline. In addition, the fluid includes an oncotic agent, such as dextran; hormones, such as thyroxin; triiodotyronine; cortisone, insulin; and electrolytes and optionally nutrients in substantially physiological concentrations in a physiologically acceptable medium. In addition, the medical fluid further includes albumin in a concentration not exceeding 5.0%, and an oxygen carrier, such as erythrocytes. Further components may be dopamine; hydrocortisone; methylprednisolone; and a vasopressor agent, such as desmopressin. The cocaine; adrenaline; and noradrenaline are present in concentrations of each about 0.010 μM to 0.100 μM, for example in a ratio of 1:1:1.

  一种用于评估和/或保存摘取的器官、组织或其部分的医用液。该液体包括可卡因或其刺激类似物、去甲肾上腺素和/或肾上腺素。此外，该药液还包括一种抗肿瘤剂，如右旋糖酐；激素，如甲状腺素；三碘酪氨酸；可的松、胰岛素；以及电解质和生理上可接受的介质中基本为生理浓度的营养物质。此外，医用流体还包括浓度不超过 5.0% 的白蛋白和氧载体，如红细胞。其他成分可以是多巴胺、氢化可的松、甲基强的松龙和血管加压剂，如去氨加压素。可卡因、肾上腺素和去甲肾上腺素的浓度各约为 0.010 μM 至 0.100 μM，例如比例为 1:1:1。